Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension

References

• Galiè N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J. 2018. DOI:https://doi.org/10.1183/13993003.02148-2018
   Google Scholar
• Wilkins MR. Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev. 2012;21(123):19–26.
   PubMedGoogle Scholar
• Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844.
   PubMed Web of Science ®Google Scholar
• Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011;140(2):301–309.
   PubMed Web of Science ®Google Scholar
• Galiè N, Horst O, Ronald J, et al., Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23): 3010–3019.
   PubMed Web of Science ®Google Scholar
• Huo Y, Jing ZC, Zeng XF, et al., Evaluation of efficacy, safety and tolerability of ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study. BMC Cardiovasc Disord. 2016;16(1): 201.
   PubMedGoogle Scholar
• Yoshida S, Shirato K, Shimamura R, et al. Long term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2012;28(6):1069–1076.
   PubMed Web of Science ®Google Scholar
• Coghlan JG, Galiè N, Barberà JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219–1227.
   PubMed Web of Science ®Google Scholar
• Chen FD, Zhou DX, Di RM, et al. Efficacy and safety of ambrisentan therapy in Chinese patients with pulmonary hypertension. Zhonghua Yi Xue Za Zhi. 2013;93(34):2736–2738.
   PubMedGoogle Scholar
• He J, Wen L, Jiang R, et al. Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41(6):493–496.
   PubMedGoogle Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 2016;1;1(9):1056–1065.
   Web of Science ®Google Scholar
• Austin C, Alassas K, Burger C. Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. Chest. 2015;147(1):198–208.
   PubMed Web of Science ®Google Scholar
• Argula RG, Karwa A, Lauer A, et al., Differences in right ventricular functional changes during treatment between systemic sclerosis–associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension. Ann Am Thorac Soc. 2017;14(5): 682–689.
   PubMed Web of Science ®Google Scholar
• Bhave NM, Visovatti SH, Kulick B, et al., Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension. Int J Cardiovasc Imaging. 2017;33(6): 847–855.
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Smiseth OA, Christopher P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
   PubMed Web of Science ®Google Scholar
• Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(8):1380–1386.
   PubMed Web of Science ®Google Scholar
• Moles VM, McLaughlin VV. Pulmonary hypertension in women: what does the cardiologist need to know? Curr Cardiovasc Risk Rep. 2017;11:10.
   Web of Science ®Google Scholar
• Pugh ME, Hemnes AR. Pulmonary hypertension in women. Expert Rev Cardiovasc Ther. 2010;8(11):1549–1558.
   PubMedGoogle Scholar
• White RJ. Estrogen: friend or foe in pulmonary hypertension? Am J Respir Crit Care Med. 2016;193(10):1084–1086.
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Zamanian RT, Damico R, et al., Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(9): 1102–1110.
   PubMed Web of Science ®Google Scholar
• Li X-Q, Li Y-J, Wang Y. Ambrisentan may improve exercise tolerance and cardiac function in patients with pulmonary hypertension. Clin Ther. 2015;37(6):1270–1279.
   PubMed Web of Science ®Google Scholar
• Ryan T, Petrovic O, Dillon JC. An echocardiographic index for separation of right ventricular volume and pressure overload. J Am Coll Cardiol. 1985;5(4):918–924.
   PubMed Web of Science ®Google Scholar
• Jia J, Han Q, Leng N, et al. Characteristics of connective tissue disease-associated pulmonary arterial hypertension: a retrospective cohort study. Int J Clin Exp Med. 2017;10(12):16254–16263.
   Web of Science ®Google Scholar
• Mitter SS, Shah SJ, Thomas JD. E/A and E/e’ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol. 2017;69(11):1451–1464.
   PubMed Web of Science ®Google Scholar